Frontlight ResearchEarly access
SuspendedPhase 1
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
Key facts
- Who runs it
- Adlai Nortye Biopharma Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its locations
- Trial code
- Status
- Suspended
- Phase
- Phase 1
- People taking part
- 32 people, planned
- Started
- 18 Jan 2022
- Ended
- Dec 2025
- Type of study
- Interventional
- Treatments tested
- AN0025
- Record updated
- 13 February 2025
- Why it stopped
- The study is not stopped but the enrollment is suspended until a further decision from sponsor.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- Diagnosed with histologically- and/or cytologically-confirmed locally advanced/locally recurrent squamous cell carcinoma or adenocarcinoma of the esophagus or of the esophagogastric junction (EGJ)
- Male or female, age≥18 years at the time of informed consent
- Have provided signed informed consent for the trial and are willing to comply with all aspects of the protocol
Who cannot take part
- Major surgery or severe trauma within 4 weeks before the first dose of study drug. Note: If participant received major surgery, they must have recovered adequately from surgery and the toxicity and/or complications requiring the intervention prior to starting study treatment
- Have received prior systemic anti-cancer therapy including chemotherapy, target therapy, immunotherapy, anti-cancer traditional Chinese medicine, and other investigational oncology agents within 4 weeks or 5 half-lives, whichever is shorter. Participants who have entered the follow-up phase of an investigational study may participate as long as it has been at least 4 weeks (or 5 half-lives, whichever is shorter) after the last dose of the previous investigational agent; Note: Participants must have recovered from all AEs due to previous therapies to ≤ Grade 1 or returned to baseline. Participants with ≤ Grade 2 neuropathy or alopecia (per CTCAE v5.0) may be eligible
- Are currently participating in a study of an investigational device within 4 prior to the first dose of study treatment
- With a history of another primary malignancy within the past 2 years, with the exception of basal or squamous cell skin cancer, or carcinoma in situ of the cervix or breast that has undergone potentially curative therapy
- Participants with known Hepatitis B or C infections, or known to be positive for Hepatitis B antigen (HBsAg)/ Hepatitis B virus (HBV) DNA or Hepatitis C antibody (HepC Ab)/ Hepatitis C virus (HCV) RNA. Active Hepatitis B is defined by a known positive HepB Ab result and known quantitative HBV DNA results greater than the lower limits of detection of the assay. Active Hepatitis C is defined by a known positive HepC Ab result and known quantitative HCV RNA results greater than the lower limits of detection of the assay
- Participants with known human immunodeficiency virus (HIV) infection (positive for HIV-1/2 antibody) or syphilis infection (positive for syphilis spiral antibody)
- Have a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
- Have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
- Have uncontrolled tumor-related pain
Where is this trial?
It has locations in one country. Choose a country to see its locations.
What happens in this trial
What the trial wants to find out
This is an open-label, multicenter, phase Ib study to evaluate the safety, tolerability, and preliminary efficacy of AN0025 in combination with chemoradiotherapy (CRT) in patients with locally advanced/locally recurrent esophageal cancer.
The group in the trial
- Patients with unresectable locally advanced/locally recurrent esophageal cancerTreatment being tested
Patients will receive AN0025 orally once daily (QD) and chemoradiotherapy followed by the maintenance of AN0025
Treatment: AN0025
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Chemoradiotherapy in Patients With Locally Advanced/Locally Recurrent Esophageal Cancer
- Record updated
- 13 February 2025